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Introduction {#sec1}
============

Vertebrates have close to 60 receptor tyrosine kinases (RTKs) that respond to a diverse set of extracellular polypeptide ligands by stimulating their intrinsic tyrosine kinase function. RTKs play key roles during embryogenesis and cellular homeostasis; they are also crucial at the origin and progression of many types of cancer ([@bib25]). Recent progress on the structural basis for EGFR, IR, and FGFR activation has emphasized the importance of RTK-specific or "private" mechanisms of activation for their catalytic domains involving flanking regions and asymmetrical and symmetrical arrangements of dimeric and higher-order oligomeric states ([@bib4], [@bib9], [@bib21], [@bib26]). The activation mechanism operating in RET in these terms is currently unclear.

In the current RET paradigm for ligand-dependent RET activation, autophosphorylation (autoP) of several tyrosine residues within the cytoplasmic domain is required for cell signaling ([@bib2], [@bib33]). For other RTKs, such as the IR and FGFR2, ligand-dependent stimulation leads to kinase activation and phosphorylation of specific tyrosine residues, which relieve repressive *cis*-inhibitory interactions to enhance catalytic activity and to promote binding of phosphotyrosine-binding domain (PTB)- and Src homology 2 (SH2)-domain-containing proteins to transmit downstream signals ([@bib11], [@bib18]). While the latter role for phosphorylation has been demonstrated for RET, its effect on catalytic activation has been only recently elucidated. In vitro, phosphorylation of the canonical RET activation loop has little effect on catalytic activity ([@bib23], [@bib35]). Indeed, RET activation-loop tyrosines Y900 and Y905 should not be considered activating, because they undergo delayed autoP and are not catalytically required ([@bib35], [@bib36]). A similar situation is found for the EGFR and non-RTK ACK1 ([@bib29], [@bib46]). In these cases, allosteric mechanisms have been identified to stimulate receptor activity independent of activation segment phosphorylation.

Cell-based studies have revealed the importance of the juxtamembrane (JM) segment in RET-receptor-mediated signaling, in particular Y687, a known phospho-tyrosine binding site for SHP2 ([@bib32]). In addition, phosphorylation at RET S696 by protein kinase A (PKA) has also been reported. Mutation of S696 affected the ability of RET to activate the small GTPase RAC1 and stimulate formation of cell lamellipodia ([@bib13]). Homozygous knockin mice carrying this mutation lacked enteric neurons in the distal colon, resulting from a migration defect of enteric neural crest cells ([@bib3]), indicating a physiological role for a PKA-RET functional crosstalk. However, structural and molecular information about allosteric mechanisms promoted by the JM region on RET kinase activity are lacking. Taking into account that the role of the JM segment of EGFR family members is distinct from that of typical RTKs because it enhances, rather than inhibits, the catalytic activity ([@bib27], [@bib42]), the nature of this coupling between the JM segment and catalytic domain for RET has not been properly explored.

In this study, we define flanking elements and phospho-sites required for RET catalytic domain activation and signaling. We show that the JM segment functions to increase RET catalytic domain activity through Y687. Structure-function analyses revealed a crosstalk among the JM hinge, αC helix, and serine phosphorylated activation loop. We demonstrate that the previously unreported S909 phospho-site arises from a dual-specificity RET kinase activity, unique among RTKs. We show that an equivalent serine in *Drosophila* RET is required for signaling in vivo. Further structural and biochemical examination revealed an RET αC hydrophobic pocket as a potential drug-targetable allosteric site.

Results {#sec2}
=======

The JM Segment Increases RET Tyrosine Kinase Activity {#sec2.1}
-----------------------------------------------------

To define the functional impact of the JM segment on RET tyrosine kinase activity, we used purified recombinant RET kinase domain (KD; residues 705--1013) and RET KD with the JM segment (JM-KD; residues 661--1012; see [Figure 1](#fig1){ref-type="fig"}A) and performed a series of biochemical experiments. First, we measured the enzymatic parameters of RET JM-KD and RET KD against an exogenous peptide ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). RET JM-KD showed a 5-fold increased catalytic efficiency (k~cat~/K~M~ constant) toward the substrate, indicating increased RET enzymatic activity promoted by the JM region. To support these results further, we performed in vitro time-course autoP assays using saturating concentrations of ATP (5 mM) and MgCl~2~ (10 mM) for 0--80 min ([Figures 1](#fig1){ref-type="fig"}B, upper panel and [S1](#mmc1){ref-type="supplementary-material"}D). Western blot (WB) analysis demonstrated increased kinetics and total phosphorylation by RET JM-KD, as indicated by levels of phospho-tyrosine 4G10 antibody. The temporal sequence of RET autoP was also evaluated by label-free quantitative mass spectrometry (LFQMS) following a previously described protocol ([@bib36]). LFQMS analysis identified tyrosine residues---Y687, Y826, Y900, and Y905---which upon RET catalytic activation were efficiently phosphorylated in a time-dependent fashion ([Figure 1](#fig1){ref-type="fig"}B, lower panel). Signal log~2~ ratios of phosphorylated peptides standardized to their non-phosphorylated counterparts were plotted relative to a zero time point ([Figures 1](#fig1){ref-type="fig"}C and 1D). As indicated by the kinetics of saturation, JM segment Y687 undergoes faster autoP than activation-loop Y900 and Y905. Furthermore, enhanced phosphorylation kinetics for Y900 and Y905 by RET JM-KD were observed compared with RET KD. In particular, a significant difference was observed in the kinetics of the double-phosphorylated activation-loop peptide. Examination of the total cumulative phosphorylation for each site demonstrated that fully phosphorylated RET JM-KD was achieved between 20 and 40 min compared with the 80--90 min required for RET KD ([Figure 1](#fig1){ref-type="fig"}B). Taken together, these data demonstrated that the JM segment increases RET catalytic activity presumably through an allosteric means. Contrary to the EGFR ([@bib20]), the JM region did not promote the formation of RET dimers in solution at protein concentrations used in the biochemical assays as assessed by dynamic light scattering (DLS; [Figure S1](#mmc1){ref-type="supplementary-material"}C). The JM segment had no appreciable impact on the stability of RET KD as reported by thermal shift experiments ([Figure S1](#mmc1){ref-type="supplementary-material"}C). However, the apparent affinity for ATP measured by isothermal titration calorimetry (ITC) was affected by 2-fold (RET JM-KD K~d~ = 37.5 ± 3.1 μM, RET KD K~d~ = 64.3 ± 10 μM; [Figure S1](#mmc1){ref-type="supplementary-material"}C). In line with these results, RET JM-KD also displayed increased enzyme kinetic parameters for ATP ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}C).

Mapping JM Elements Required for RET Catalytic Activation {#sec2.2}
---------------------------------------------------------

To map key residues within the RET JM region, we generated a series of deletions and performed biochemical analyses. First, enzymatic assays were performed using an ABL-derived peptide, used previously as a good surrogate substrate for RET. Comparison of the catalytic efficiency (k~cat~/K~M~) among the different RET JM-KD deletions demonstrated that full-length JM segment starting at residue 661 (JM661) was required to achieve maximal catalytic activity ([Figures 2](#fig2){ref-type="fig"}A and 2B). Time-course autoP assays (0--80 min) using RET phospho-specific antibodies were performed to validate the enzymatic assays and LFQMS data. More rapid and elevated phosphorylation levels were observed by RET JM661 as indicated by total phospho-tyrosine and phospho-specific RET Y905 and Y981 antibodies, respectively ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C). In this context, the shorter RET JM698 behaved similarly to RET KD, showing slower kinetics. Faster Y905 and Y981 autoP was observed by RET JM661 compared with RET JM678, and even more significantly with RET JM698 or RET KD. These results confirmed an increased RET catalytic activity because of the JM segment and implicate the region between residues 661 and 697. Further truncations targeting the transition toward the RET catalytic core, especially residues 705--712, were evaluated in expression analyses and in autoP assays. While the recombinant RET catalytic domain starting at residue 709 was stable in solution, the construct starting from residue 713 gave rise to an unstable protein ([Figure S2](#mmc1){ref-type="supplementary-material"}A). The RET catalytic domain starting at residue 709 displayed slower kinetics of phosphorylation compared with that beginning at residue 705 ([Figure S2](#mmc1){ref-type="supplementary-material"}B).

Recombinant glutathione *S*-transferase (GST)-RET KD fusions with different lengths of the JM segment were used to assess the impact of "forced" dimerization on RET catalytic activity in solution. GST-RET fusions displayed faster kinetics and increased levels of phosphorylation than the untagged proteins ([Figures 2](#fig2){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}D). However, such enhanced kinetics were independent of the length of the JM segment. Although in principle this artificial system could lead to forced dimerization by the GST modules to dominate and override the effect of JM segment on RET activity, these data indicate that dimerization is not driving the increased activity promoted by the JM region in solution.

The JM Segment Increases RET Catalytic Activity without Affecting Substrate Presentation {#sec2.3}
----------------------------------------------------------------------------------------

The JM segment could potentially increase RET autoP by promoting a better substrate. To assess whether the JM segment also influences the substrate presentation properties of RET, we performed phosphorylation rescue experiments in *trans* using catalytically deficient RET K758M variants as substrates ([@bib36]). Consistent with earlier experiments, RET JM-KD-containing residues 661--677 were more active against catalytically deficient RET intracellular domain (ICD) K758M (i.e., substrate) than RET KD ([Figure S3](#mmc1){ref-type="supplementary-material"}A). A reciprocal experiment was then performed using an active RET ICD against a catalytically deficient RET K758M in either JM-KD or KD context ([Figure S3](#mmc1){ref-type="supplementary-material"}B). No significant differences were observed between the two substrate variants with or without the JM segment, indicating that the JM region makes RET kinase a better enzyme and not a better substrate for autoP.

JM Segment Y687 Promotes RET Catalytic Activity {#sec2.4}
-----------------------------------------------

The activating JM segment spanning residues 661--697 contains Y687, a known autoP site. To evaluate the functional role of this phospho-site in RET catalytic activity, we made Y687F mutant variants. AutoP assays of wild-type (WT) or Y687F mutants in a RET JM661 or JM678 context were compared with RET JM698 and showed a significant detrimental effect for Y687F mutants using both total phospho-tyrosine and phospho-specific RET Y905 and Y981 antibodies, respectively. In RET JM661, the effect of the Y687F mutant was reduced, suggesting 661--678 could partially compensate for the loss of Y687. Next, a phospho-specific polyclonal antibody was raised against a phospho-Y687 peptide. As expected, the phospho-specific Y687 antibody showed no signal for Y687F mutants nor RET JM698, but increased signal for WT RET JM661 compared with RET JM678 ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}C). Previous data showed no impact of Y687 on RET ICD activity ([@bib36]). A dependency on Y687 is seen only in the absence of RET C-terminal (CT) sequences. One explanation would be if the JM and CT segments were in a spatially close proximity and could exhibit a compensatory effect masking a Y687 functional role (see [Figure 5](#fig5){ref-type="fig"} and [Discussion](#sec3){ref-type="sec"}). Next, we assessed the effect of single Y900F, Y905F, and Y981F and double Y900/905F mutants on RET JM-KD activity. In contrast with the detrimental effect observed for Y687F mutants, replacement of the other phospho-sites (Y/F) did not disrupt RET autoP ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}D). Of note, double activation-loop RET JM-KD Y900/905F mutant showed significant lower levels of Y981 phosphorylation despite no effect on total phosphorylation. More importantly, RET JM661-KD Y900/905F showed WT levels of phospho-Y687 and total phosphorylated RET kinase, indicating the JM segment is able to rescue the activity in *cis* of the catalytically deficient RET KD Y900/905F mutant ([@bib35], [@bib36]). These data demonstrate that crosstalk (i.e., rescue) between the JM segment and the activation-loop is required for RET catalytic function. Further evidence of coupling between the JM and activating segments was obtained by testing a triple RET JM-KD Y687F/Y900/905F mutant for tyrosine kinase activity ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}E). Crucially, RET JM-KD Y687F was not able to rescue the catalytically deficient Y900/905F mutation. Altogether, these data demonstrate that Y687 is required for a proper allosteric input by the JM segment on RET catalytic activity able to overcome and stabilize a Y900/905F-deficient activation-loop mutant.

Crystallographic Identification of an Unexpected Activation-Loop Phospho-S909 {#sec2.5}
-----------------------------------------------------------------------------

We have determined two similar crystal structures of a construct containing the RET JM region and KD (amino acids 659--1013) at 3.3 and 2.95 Å, respectively ([Table 1](#tbl1){ref-type="table"}). Both crystal structures contained the PP1 tyrosine kinase inhibitor in the nucleotide-binding pocket, had an ordered proximal portion of the RET JM segment, and had a hyper-phosphorylated status with four sites phosphorylated (Y809, Y905, S909, and Y928) ([Figures 4](#fig4){ref-type="fig"}A and 4B). The structures differ slightly in resolution and in the occupancy of the phospho-S909 site. The enhanced multi-site phosphorylation status was surprising when compared with previously solved crystal structures of mono-phosphorylated RET catalytic domain (see PDB: [2IVT](pdb:2IVT){#intref0010}, [2IVU](pdb:2IVU){#intref0015}, [2IVV](pdb:2IVV){#intref0020}, and 4CKI), but consistent with biochemical data, indicating higher RET JM-KD levels of tyrosine kinase activity compared with RET KD ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Residue Y809 is located within the RET hinge connecting the N-lobe and C-lobe of the RET KD, whereas Y905 and S909 are within the RET activation loop, and Y928 follows the WMAIE motif at the end of the activation segment between helixes α4 and α5 ([@bib14]). The presence of these phosphorylation sites impacts mainly on the activation-loop conformation detaching it from the body of the catalytic core without affecting the conformation of the hinge, as described later ([Figures 4](#fig4){ref-type="fig"}A, 4B, and [S4](#mmc1){ref-type="supplementary-material"}A). Previously solved phosphorylated RET KD crystal structures (PDB: [2IVT](pdb:2IVT){#intref0025}, [2IVV](pdb:2IVV){#intref0030}, and 2IVU) showed phospho-Y905 tethers several basic side chains including R770 from the αC helix and residues R897 and K907 from the activation loop. In the crystal structures presented in this study, phospho-S909 displaces phospho-Y905 and adopts an approximate equivalent position by engaging activation segment residues R897 and R912, as well as R873 from the HRD motif instead ([Figures 4](#fig4){ref-type="fig"}B, 4C, and [S4](#mmc1){ref-type="supplementary-material"}B). In this situation, Y905 does not engage the side chain of the αC helix R770; as a consequence, phospho-Y905 projects away from the body of the RET kinase to mimic a fully solvent-accessible conformer. The second unexpected phosphorylation site at Y928 is positioned beneath the tethered phospho-S909 and is likely to further disrupt interactions of phospho-Y905 with the activation loop. Phospho-Y928 forms hydrogen bonds with side chains of R873 (HRD motif) and activation loop R897 at the top and with H926 from beneath. Its partially buried position indicates the activation loop must have adopted an accessible conformation to fully expose Y928 to undergo phosphorylation. These data are consistent with a recent study where we showed enhanced substrate presentation in *trans* (i.e., activation-loop out conformer) in solution by an oncogenic RET M918T mutant targeting the P+1 substrate-binding pocket ([@bib36]).

Phospho-S909 Arises from an Intrinsic RET Dual-Specificity Kinase Activity {#sec2.6}
--------------------------------------------------------------------------

Full-length RET and RET ICD are known to be serine phosphorylated in cells and in vitro, respectively ([@bib36], [@bib40]). S909 is invariant in all RET sequences and is found only within a minority of RTKs in the human kinome (e.g., FGFR4, ROR1, and HER3). We did not detect S909 phosphorylation by mass spectrometry; however, when we used a specific antibody against an RET phospho-S909 epitope (pSQG), weak basal phospho-serine activity was observed for RET WT ([Figure 4](#fig4){ref-type="fig"}D, upper panel). RET S909 phosphorylation was dependent on the catalytic status of the receptor as indicated by lack of signal of a kinase-dead K758M mutant and was highly specific for S909 (i.e., no signal by a S909A mutant). These data suggested that, contrary to a constitutive phosphorylation event in *trans* on S909 by an unknown serine-threonine kinase as we initially hypothesized, RET could be a dual-specificity kinase that can autophosphorylate on S909. To test this hypothesis, we performed time-course autoP assays with RET ICD WT versus K758M and S909A mutants ([Figure 4](#fig4){ref-type="fig"}D, lower panel). As predicted from previous results, RET K758M showed no tyrosine kinase activity compared with RET WT and S909A mutant, which showed similar time-dependent tyrosine autoP ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Crucially, when a phospho-specific RET S909 epitope antibody was used, a time-dependent effect was seen only for RET WT, which showed phospho-serine levels saturating at 60--90 min after stimulation. In contrast, no signal was seen in the case of RET K758M or S909A mutants. Taken together, these data demonstrated that phospho-S909 arises from an intrinsic RET dual-specificity kinase activity not previously reported for an RTK.

Structure-Function Validation of RET JM-KD Crystal Structure {#sec2.7}
------------------------------------------------------------

To interpret the increased JM-KD kinase activity from the new structure, we considered whether αC R770 side chain, which coordinates phospho-Y905 in the RET KD structure, could instead make contacts with the JM segment, thereby stabilizing a more active conformer independently of phospho-Y905. Assessing the functional impact of an R770A mutant in the context of both RET JM-KD and RET KD, we found the mutant was selectively impairing RET JM-KD activity but had not a measureable detrimental effect on RET KD ([Figures 4](#fig4){ref-type="fig"}E and [S4](#mmc1){ref-type="supplementary-material"}F). These data implicate R770 in engaging the JM segment to increase RET catalytic domain activity. Second, we evaluated whether S909 was required for RET tyrosine kinase activity in vitro. Surprisingly, we did not observe any significant effect of the S909A mutant on RET activity in either enzyme kinetics using peptide substrates or in autoP assays ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). Further enzymatic experiments using purified recombinant RET KD with increasing concentrations of activation-loop-derived S909 phospho- and non-phospho-peptides confirmed these results further ([Figure S4](#mmc1){ref-type="supplementary-material"}E). These data indicate that analogously to RET KD tyrosine autoP sites, S909 is not intrinsically required for catalytic activity. We also considered that redundancy of phospho-S909 with phospho-Y905 could mask such a critical role. The latter possibility was further excluded by the lack of any functional effect observed by an RET JM-KD Y905F/S909A double mutant ([Figure S5](#mmc1){ref-type="supplementary-material"}A). An equally plausible explanation is that multi-site phosphorylation of the RET activation segment could play a role in releasing phospho-Y905 or even phospho-S909 acting as a docking or adaptor site required for downstream signaling (see [Discussion](#sec3){ref-type="sec"}).

Structural Identification and Functional Validation of RET αC Hydrophobic Patch {#sec2.8}
-------------------------------------------------------------------------------

The JM-KD structure revealed contacts from a short segment of the proximal JM region (residues D707 to W717) with a hydrophobic patch composed of residues from different structural elements including β4 (L790), β5 (L800, L801, L802), and αC helix (L769, L772, L773, F776, L779) ([Figures 5](#fig5){ref-type="fig"}A and 5B). This αC hydrophobic patch is present in many tyrosine and serine-threonine kinases and is frequently a site of regulation to assemble a functional regulatory (R) spine ([@bib22], [@bib24], [@bib43]). Intramolecular contacts with this hydrophobic patch arise from interaction with either N- or C-terminal sequences flanking the KD ([@bib21]). We noticed a passing similarity between RET αC hydrophobic patch-JM-segment interaction and the PIF pocket-hydrophobic motif interaction found in AGC kinases first described for the PDK1 serine-threonine kinase (where PIF is defined as the PDK1-interacting fragment) and PKA ([@bib22], [@bib6]). Superposition of the RET JM-KD crystal structure with the PKA catalytic domain (PDB: [1ATP](pdb:1ATP){#intref0035}) suggests an equivalence between residues of the PKA hydrophobic motif located at its C terminus to contact the αC helix with those observed in the RET JM segment that engage the hydrophobic αC patch ([Figures 5](#fig5){ref-type="fig"}A and 5B). Our interest in this similarity was stimulated by the development of selective drugs against the PDK1 PIF pocket, suggesting the potential for targeting the same region of RET by chemical inhibitors as an alternative route to RET nucleotide pocket inhibition.

To biochemically probe the role of this αC hydrophobic patch on RET tyrosine kinase activity in vitro, we engineered individual mutants L769A, L772A, and L773A and double mutants L769/772A and L769/773A, and assessed the effect on autoP and enzyme kinetic assays ([Figures 5](#fig5){ref-type="fig"}C and 5D). Out of the three single-point mutants, L772A had a profound detrimental effect compared with WT and L769A, whereas L773A had a marked gain-of-function effect on RET kinase activity. The proximity of L772 and L773 on the αC helix and their opposing effects suggests a subtle conformational alteration of αC would be important for R-spine assembly and hence RET activation. We note that the insulin receptor kinase L1045 (structural equivalent to L773 of RET) directly contacts JM segment Y984 side chain stabilizing an auto-inhibited form ([@bib27]). By analogy, L773 could also potentially engage Y687 bound in a similar manner; this would explain why a L773A mutant stimulates RET activity (see [Discussion](#sec3){ref-type="sec"}). In contrast, L772A gave rise to a loss-of-function effect. We hypothesize that an RET L772A mutant would not create a constitutively active RET (based on the BRAF paradigm, see [Discussion](#sec3){ref-type="sec"}), but would rather impact on the catalytically required K758-E775-D892 tether and would therefore have a similar impact to the loss-of-function K758M mutant. Double mutants L769/772A and L769/773A were both impaired in their catalytic activity. The contribution of residues from the proximal JM region (i.e., D707, F709, and I711) was also evaluated, revealing lack of functional effect ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). These data suggest that other N-terminal residues from the JM segment not captured in the crystal structure may be relevant for this interaction (e.g., Y687). Alternatively, residues proximal to the transition between JM segment and catalytic domain boundary could also be implicated (see [RET W717 Contributes to the Assembly of the JM Hinge and R-Spine](#sec2.9){ref-type="sec"} and [Discussion](#sec3){ref-type="sec"} sections). These data implicate residues L772 and L773 from the αC helix as key determinants in achieving an active conformer and may potentially, by analogy to PDK1, provide an alternative druggable pocket to target within RET.

RET W717 Contributes to the Assembly of the JM Hinge and R-Spine {#sec2.9}
----------------------------------------------------------------

Further structural examination of the αC hydrophobic patch highlighted W717, a highly conserved residue preceding the β-1 strand in many protein kinases including SRC, BTK, EGFR, and BRAF that separates the JM segment from the core catalytic domain ([Figure 1](#fig1){ref-type="fig"}A). In the case of BRAF (W342), this residue is important for capping the R-spine in an active conformation and is preceded by a set of phosphorylated residues that are important for dimerization ([@bib17]). In RET, W717 is preceded by a short sequence that engages the αC hydrophobic pocket that contains also the translocation site found in oncogenic RET fusions. To test the function of W717, we generated W717A and W717F mutants in the context of RET JM-KD and found that, contrary to W717F, the W717A mutant had a profound detrimental effect on RET phospho-tyrosine activity compared with WT ([Figure 6](#fig6){ref-type="fig"}A). These data indicate that W717 is required for RET catalytic activity. One plausible scenario is that W717 would be required for the proper alignment of the JM-proximal hydrophobic motif (DALKIL) to the αC hydrophobic patch (i.e., PIF-like pocket). Although correct in principle, this is unlikely based on the lack of effect in RET activity seen by alanine mutants targeting the DxLxI motif sequence ([Figure S6](#mmc1){ref-type="supplementary-material"}), which suggest that residues farther up in the JM segment (e.g., Y687) make important contacts with the catalytic core ([Figure 3](#fig3){ref-type="fig"}). Alternatively, W717 would be required for docking onto and proper alignment of the R-spine in the active conformation, following the BRAF paradigm ([Figure 6](#fig6){ref-type="fig"}A). We hypothesize that mutating W717 by alanine and not by phenylalanine will perturb the R-spine side chain stacking and, as a consequence, impact on RET activity. Examination of the crystal structure ([Figure 6](#fig6){ref-type="fig"}B) revealed that in RET the R-spine is composed of four hydrophobic residues originating from the αF helix connecting N- and C-lobes; these residues include H872 (from the catalytic HRD motif), F893 (from the DFG motif), L779 (αC helix), and L790 (β-4 strand). W717 caps from the top the R-spine in a linear tetrad compatible with an active DFG in conformation of the kinase ([@bib41]). It is further preceded by D714 adjacent to the fusion site between L712 and E713, which forms an important salt bridge with αC K780, a specific feature lacking in previously solved RET catalytic domain crystal structures. The combined effect of both W717 docking and the D714-K780 tether locks the hinge between the proximal JM segment and N-terminal residues of the catalytic core. In this scenario it is plausible also to hypothesize that perturbation of the hinge by the W717A mutant, contrary to hydrophobic motif DxLxIx alanine mutants, results in a non-compatible JM-proximal segment alignment with N-terminal residues of the catalytic core and a consequent alteration of the R-spine. How perturbation of the R-spine linear architecture results in catalytic inefficiency is likely an indirect effect on both the catalytic (C)-spine and the catalytically required K758 (β-3 strand)-E775 (αC helix)-D892 (DFG motif) tether, which links both spines and the nucleotide moiety ([Figure 6](#fig6){ref-type="fig"}C). From these data we conclude that W717 is an important residue for RET function by playing a role in the assembly of the JM hinge and R-spine.

Activation-Loop Serine Phosphorylation Is Required for RET Signaling In Vivo {#sec2.10}
----------------------------------------------------------------------------

S909 is a novel autoP site that arises from intrinsic dual-specificity kinase activity exhibited by RET in vitro ([Figure 4](#fig4){ref-type="fig"}D). Functional assays of a S909A mutant excluded a direct role of S909 on RET catalytic activity ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). These results are consistent with data for mutants targeting RET KD tyrosine autoP sites ([Figure 3](#fig3){ref-type="fig"}B) and suggest phospho-S909 could act as a docking or alternatively a substrate site for effector proteins important for RET signaling. Given the high conservation of S909 in all RET sequences and its consistent occupancy, we assessed whether S909 had a role in RET downstream signaling. We therefore used a *Drosophila* Ret^2B^ (*dRet*^*2B*^; *dRet M955T*) fly model to assess whether mutation at residue S946 (equivalent to human RET S909) could influence in vivo the aberrant phenotype promoted by oncogenic *dRet*^*2B*^. We employed a pUAST-attB fly vector system to allow specific site insertion of the transgene into the fly genome ([@bib7]). Overexpression of *dRet*^*2B*^ in the developing eye using the glass multiple reporter (GMR) Gal4-815 promoter (GMR-Gal4-815 \> *dRet*^*2B*^) led to extensive mispatterning and positioning of ommatidia resulting in a "rough eye" phenotype in the adult fly compared with the driver-line control. When we generated a transgenic fly expressing a double mutant *dRet*^*2B/S946A*^ (*dRet M955T/S946A*), the aberrant rough eye phenotype was completely rescued ([Figure 7](#fig7){ref-type="fig"}A). Further ectopic overexpression of *dRet*^*2B*^ in the peripodial cells of the developing wing epithelium under the control of the 765 promoter (*765\>dRetM955T)* led to an increase in the number of aberrant veins ([Figure 7](#fig7){ref-type="fig"}B, arrows) within the adult wing ([Figures 7](#fig7){ref-type="fig"}B and 7C). As anticipated, ectopic expression of the double mutant in the developing wing (*ptc*765\>*dRet M955T/S946A*) resulted in the abolition of the aberrant phenotype. To assess whether a signaling defect was associated with S946A (S909A in humans), we expressed ectopically dRET WT, M955T, and M955T/S946A in S2 insect cells, together with an *Actin* promoter-driven *Gal4* construct, and performed WB analyses. We observed a significant detrimental effect on the double mutant dRet M955T/S946A compared with oncogenic dRet M955T in downstream signaling as indicated by total phospho-tyrosine antibody, and also on dRet phosphorylation, as indicated by RET Y1015 and Y1062 phospho-specific antibodies ([Figure 7](#fig7){ref-type="fig"}D). These data indicate that an S909 phosphorylation event plays a crucial role in RET signaling in vivo. These results point toward further complexity through interplay with RET phospho-tyrosine sites, or alternatively as a docking and/or phospho-site for a yet unknown effector that impacts on RET signaling.

Discussion {#sec3}
==========

To identify unique features of RET tyrosine kinase activation, we have applied biochemical, structural, and biophysical analyses, together with an in vivo model for RET hyper-activation. We show that the JM segment functions to increase RET tyrosine KD activity without affecting substrate presentation in *trans*. Fully phosphorylated RET JM-KD appears rapidly, between 20 and 40 min, compared with the 80--120 min required for core RET KD ([Figure 1](#fig1){ref-type="fig"}B). This increased activity promoted by the JM segment, contrary to the EGFR ([@bib20], [@bib38]), does not appear to result from stable dimer formation in solution ([Figure S1](#mmc1){ref-type="supplementary-material"}C) and is independent of "forced" dimerization through the presence of a GST tag ([Figure 2](#fig2){ref-type="fig"}D). Our results are consistent with VEGFR2, where in solution the kinetics of autoP is significantly enhanced by the JM region ([@bib39]). Comparing these data with the slower overall phosphorylation kinetics of RET ICD ([@bib36]) suggests the C-terminal (CT) segment could act as a negative regulator of RET catalytic domain activity and restrain by competition JM segment activating input. The RET JM region appears not to play a *cis*-inhibitory role as observed for KIT and MET ([@bib10], [@bib19]) but is likely to stabilize an active form of RET in a manner that is dependent on Y687. We argue that autoP is not prevented by a non-phosphorylated conformer of JM segment on Y687, but that timely phosphorylation of JM segment on Y687 leads to a conformation contributing to a more active RET kinase. This is supported by the observation that Y687 is required for the JM segment to rescue a catalytically deficient RET KD lacking both activation-loop tyrosines (Y900/905F). Furthermore, a RET JM-KD Y687E mutant (mimicking a constitutive phospho-Y687) showed a significant decrease on tyrosine kinase activity, which indicated that Y687 is a tightly regulated autoP site. We hypothesize that constitutive phosphorylation on Y687 results in a detrimental effect on activity because of the lack of required contacts between JM segment and RET catalytic core prior and during kinase activation ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Furthermore, the dependency seen by RET JM-KD, but not RET KD, on αC R770 implicates its side chain in engaging the JM segment to increase RET catalytic domain activity. Further evidence for the *cis* effect of the JM segment in RET activation includes: (1) phosphorylation rescue experiments in *trans* using as substrate catalytically deficient versions (i.e., K758M) of RET JM-KD and RET KD ([Figure S3](#mmc1){ref-type="supplementary-material"}B) did not show significant differences because of the JM segment, and (2) the presence of the RET JM-segment effectively rescues an otherwise catalytically-deficient RET mutant bearing a double-tyrosine (Y900/905F) substitution in the activation-loop. Note this is contrary to the rescue experiment in *trans* of catalytically deficient K758M kinase versions, which cannot be rescued in *cis* by either JM segment ([Figure S3](#mmc1){ref-type="supplementary-material"}) or oncogenic mutations ([@bib36]).

The trajectory of the proximal part of the RET JM-segment resembles to some extent that seen in the IR JM-KD crystal structure (PDB: [1P14](pdb:1P14){#intref0040}) ([@bib27]). In the IR crystal structure, JM-Y984 docks into the αC hydrophobic patch in *cis* (adopting an equivalent position to RET F776) and forms a network of hydrogen bonds between residues from the αC helix and proximal JM segment. These interactions provide steric restraints preventing αC from assuming a catalytically competent position. A recent study has shown, however, that the JM-IR can also adopt a JM-out conformer contacting the αC of a second receptor molecule and is able to stabilize an active catalytic dimer ([@bib9]). This role for the IR JM-segment in *trans* tethers a quite distinctive symmetric active dimer compared with that observed for the asymmetric EGFR dimer ([@bib20]). This recent JM-IR structure (PDB: [4XLV](pdb:4XLV){#intref0045}) shows how the JM-segment pivots about the equivalent residue to RET W717 ([@bib17]) to make intermolecular contacts with the αC hydrophobic patch from a second molecule. This resembles in *trans* an extended stretch of the proximal JM region seen in our RET JM-KD crystal structure. Our interpretation is that in the absence of a stable RET JM-KD dimer in solution or in the crystal, the JM-segment collapses onto the αC helix in *cis* in the crystal lattice. Our data pointed also at the critical RET αC hydrophobic pocket as being sensitive to allosteric input from JM-segment elements, possibly including Y687. This hydrophobic pocket has the potential to be targeted by small molecules, because there are precedents for PDK1 where allosteric inhibitors against an equivalent site are already available ([@bib8]).

Chromosomal translocations involving the RET exons 12--21 are found in human thyroid and lung cancers ([@bib31], [@bib37]). These gene rearrangements fuse a variety of unrelated coiled-coil proteins within the same RET intron, thereby removing exons 1--11, including the JM segment. Our data are consistent with a scenario in which removing the JM segment, rather than eliminating an autoinhibitory element, replaces it with a more potent dimerizing motif that stabilizes a RET dimer independently of ligand and transmembrane region. For the IR, its JM segment extends away from the kinase core pivoting about a conserved VPDEWE motif to engage a second kinase molecule via contacts to the αC helix. A network of salt-bridge interactions at the pivot point involves the VPDEWE motif to help stabilize a conformation associated with an activated IR tyrosine kinase. The equivalent sequence for RET, EDPKWE, contains the fusion site (between L712 and E713) of many RET translocations that eliminate RET exons 1--11 ([@bib31]). Such fusions add a dimeric coiled-coil region just prior to D714 and W717 that would lock permanently the JM hinge and R-spine into a DFG-in conformer resulting in a hyperactive RET, no longer localized at the plasma membrane. These findings have important drug discovery and therapeutic implications as perturbation of the JM hinge and consequent effect on adequate R-spine assembly could be a new drug-targetable strategy against oncogenic RET.

The JM-KD crystal structure shows two unexpected phosphorylation sites, Y928 and S909, both invariant RET residues. Both are in close proximity and engage basic residues otherwise found in the core RET KD structures engaged by phospho-Y905 ([Figures 4](#fig4){ref-type="fig"}A and 4B; [Figure S4](#mmc1){ref-type="supplementary-material"}B). In particular, the unconventional activation-loop S909 phospho-site engages the HRD motif in what it seems to be a unique active conformation promoting both regulatory-spine assembly and accessibility to phospho-tyrosine binding modules. As a consequence, Y905 is displaced, adopting a solvent-accessible conformer competent for a signaling function rather than playing an activating role.

Analyses of RET sequences flanking the invariant protein kinase RD motif establish it as tyrosine kinase (HRDLAARN or HRDLRAAN) rather than a serine-threonine kinase (H/YRDLXXN) ([@bib14], [@bib28]). There are precedents for dual-specificity kinase activity among the cyclin-dependent kinase (CDK), mitogen-activated protein kinase (MAPK), glycogen synthase kinase (GSK3), CDC-like kinase (CLK) group of protein kinases (CMGC) that include the mitogen-activated protein kinase (MAPK) and DYRK kinase members. The latter examples phosphorylate exclusively serine and threonine side chains in their substrates but are able to autoP on tyrosine ([@bib16]). More recently, a non-receptor tyrosine kinase Syk has been shown to exhibit dual-specificity kinase activity ([@bib15]). In our study, robust biochemical examination revealed that S909 is an autoP site that arises from an intrinsic RET dual-specificity kinase activity. This is consistent with a recent study reporting that RET can phosphorylate AP2 in *trans* on threonine ([@bib5]). This dual-specific activity can generate phospho-S909 in vitro. However, phosphorylation on RET S909 was not catalytically required ([Figures S4](#mmc1){ref-type="supplementary-material"}C--S4E), consistent with other serine-to-alanine mutants targeting the JM segment ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Further efforts are needed to establish whether phospho-S909 can act as a docking for a yet-unknown effector protein involved in RET signaling. Interestingly, when we evaluated an RET S909D mutant, a marked increase in RET JM-KD phospho-tyrosine activity was observed ([Figure S5](#mmc1){ref-type="supplementary-material"}B). These data suggest that a phosphorylation event on S909 in *trans* can contribute to RET tyrosine kinase activity and signaling in vivo. To explore further this hypothesis, we employed an in vivo model and found that mutating this residue in *Drosophila* Ret (*dRet*) has a deleterious effect on the *dRet*^*2B*^ (*dRet M955T*) oncogenic phenotype, a well-established model of transformation. In particular, *dRet M955T/S946A* efficiently rescued the phenotype of *dRet*^*2B*^ using alternative promoters.

Overall, our structure-function analyses and in vivo experiments have revealed complex elements in the mechanism of RET activation and signaling. Allosteric inputs from the JM-segment and activation-loop S909 contribute to kinase function. We show that phospho-S909 is an autoP site arising from an intrinsic dual-specificity RET kinase activity and appears to play key roles in oncogenic signaling. Our study also suggests that targeting the αC hydrophobic pocket together with the JM hinge using small molecules to manipulate RET kinase activity may be a productive approach for either blocking oncogenic forms of RET or stimulating RET activity in Hirschsprung's disease (HSCR) and neurodegenerative Parkinson's disease (PD).

Experimental Procedures {#sec4}
=======================

Expression and Purification of Recombinant Protein {#sec4.1}
--------------------------------------------------

Protein expression was carried out using Sf9 insect cells following a previously described protocol ([@bib23]). Codon optimized human RET9 isoform intracellular domain (ICD residues 661--1072), different lengths versions of the RET JM-KD (661 to 698--1012) and RET KD core (705--1013) WT, and the indicated mutants proteins were purified following a protocol previously described ([@bib36]).

Mass Spectrometric Label-free Quantitation {#sec4.2}
------------------------------------------

Mass spectrometry procedures were performed as previously described ([@bib36]).

Autophosphorylation Assays, SDS-PAGE, and Western Blotting {#sec4.3}
----------------------------------------------------------

Unless otherwise indicated, time-course autoP assays were performed with recombinant purified protein as previously described ([@bib36]). Western blotting was performed with the indicated antibodies as previously described ([@bib34], [@bib35]). A specific antibody against RET phospho-S909 epitope (pSQG) was from Cell Signaling. Data represent at least two to six independent experiments (n) using different protein preparations. In addition to the quantitation of WB data shown on [Figures 4](#fig4){ref-type="fig"}D and [6](#fig6){ref-type="fig"}A, further quantitation of the indicated WB analyses can also be found in the [Supplemental Information](#app3){ref-type="sec"}.

Enzymatic Kinase Assays {#sec4.4}
-----------------------

Enzyme kinetic experiments were performed as previously described ([@bib36]).

ITC {#sec4.5}
---

ITC experiments were performed as previously described ([@bib36]).

Dynamic Light Scattering and ThermoFluor Assays {#sec4.6}
-----------------------------------------------

To determine protein stability, we performed thermal shifts assays as previously described ([@bib34], [@bib36]). Molecular weight determination in solution was performed by DLS using different RET protein concentrations.

Crystallization, Diffraction, Data Collection, and Processing {#sec4.7}
-------------------------------------------------------------

Crystals of the phosphorylated RET JM-catalytic domain (residues 659--1013) were grown at 22°C by vapor diffusion in sitting drops containing crystal 1 (5FM2), 1 μL protein stock solution (6 mg/ml) mixed with 1 μL reservoir solution (1.5 M ammonium sulfate, 0.1 M BIS-TRIS propane \[pH 7.0\]); the protein stock solution also contained 2.5 mM ATP and 5 mM MgCl~2~. Crystal 2 (5FM3) comprised 0.8 μL protein stock solution (5 mg/ml) mixed with 0.8 μL reservoir solution (1.2 ammonium sulfate, 0.1 M tri-sodium citrate \[pH 5.43\]). The crystals were cryoprotected in 25% glycerol in reservoir solution for several minutes and flash frozen in liquid nitrogen, and X-ray datasets were collected at the I-24 beamline of the Diamond Light Source Synchrotron (Oxford, UK). Data collection and refinement statistics are summarized in [Table 1](#tbl1){ref-type="table"}. The dataset was indexed with MOSFLM and scaled with SCALA ([@bib45]). Molecular replacement was carried out using the atomic coordinates of the phosphorylated RET KD (PDB: [2IVT](pdb:2IVT){#intref0050}) in PHASER ([@bib30]). Refinement was carried out by using Phenix ([@bib1]). Model building was carried out in COOT ([@bib12]). Model validation used PROCHECK ([@bib44]), and figures were prepared using the graphics program PYMOL (<http://www.pymol.org>).

*Drosophila* Experiments {#sec4.8}
------------------------

pUASTattB-*dRetM955T* (*dRet*^*2B*^) and double mutant pUASTattB-*dRetM955T/S946A* constructs were generated by site-directed mutagenesis using the following primers: M955T forward 5′-GTGCCCGTCAAGTGGACGGCTCCGGA-3′, M955T reverse 5′- TCCGGAGCCGTCCACTTGACGGGCAC-3′, S946A forward 5′- GCCTATTTAAAGAGAGCCCGAGATCGTGTGCCC-3′, and S946A reverse 5′- GGGCACACGATCTCGGGCTCTCTTTAAATAGGC. Transgenic flies were generated using P-element-mediated (pUAST) transgenesis by BestGene. *Drosophila* stocks and crosses were maintained at 25°C, unless stated otherwise. For ectopic expression of the various transgenes in the developing *Drosophila* wing, *dRet* transgenic flies were crossed with the Gal4 C-765 driver (36523, Bloomington). Adult wings were dissected, mounted, and imaged at 4× magnification using the EVOS cell imaging system. For ectopic expression of the *dRet*^2B^ and *dRet*^2B^ *S946A* in the developing eye, the transgenic flies were crossed with the GMR-Gal4 815 (weak) driver and maintained at 18°C. Eye phenotypes were analyzed by light microscopy of whole mounts.

Ectopic Expression in S2 Cells {#sec4.9}
------------------------------

pUASTattB-*dRet* WT, M955T, and M955T/S947A constructs (400 ng) were co-transfected together with an *Actin*-promoter-driven *Gal4* plasmid (400 ng) as indicated into S2 cells using Effectene and following manufacturer's instructions. Data represent three independent experiments.

Statistical Analyses {#sec4.10}
--------------------

Graphs and statistical analyses were done using Prism GraphPad.

Author Contributions {#sec5}
====================
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Accession Numbers {#app1}
=================

The crystallographic coordinates and structure factors for the RET JM-KD crystal structures reported in this paper are PDB: [5FM3](pdb:5FM3){#intref0060} and [5FM2](pdb:5FM2){#intref0065}, respectively (<http://www.pdb.org>).
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![The JM Segment Enhances RET Catalytic Domain Activity In Vitro\
(A) Alignment of selected JM sequences from human RTKs highlighting conserved residues in bold, serine residues in blue, and tyrosine in red. Selected acidic side chains at an equivalent position to Y687 of RET are also shown in red. Schematic diagram of discrete RET functional domains together with the phospho-sites (red spheres) analyzed in this study. White spheres correspond to sites outside the scope of this study. Residue numbering corresponds to human RET9 sequence (NP_065681.1). Dashed arrow depicts the transition from the JM segment to the RET catalytic core. Lower panel depicts RET constructs used in this study as indicated: RET intracellular domain (ICD; 661--1,072), RET kinase domain (KD; 705--1,013), and RET JM-KD variants starting at 661, 678, and 698, respectively. For crystallization purposes, an RET JM659-KD (659--1,013) construct was used in this study (^∗^). Previously solved RET catalytic domain crystal structures used an RET KD (705--1,013) construct.\
(B) Western blot (WB) analyses of purified recombinant RET JM-KD and RET KD (2.5 μM) treated with saturating concentrations of ATP (5 mM) and MgCl~2~ (10 mM) for 0--80 min using the indicated antibody. Total amount of protein was assessed by Coomassie blue staining (upper panel). Lower panel shows a global time-dependent analysis by LFQMS (showing accumulative phosphorylation for each site) of the same samples. Data are representative of multiple independent experiments (n): n \> 6 for WB and n = 3 for LFQMS.\
(C and D) Phosphorylation kinetics of individual sites from (B) is shown. Data represent the mean log~2~ ratios of phosphorylated peptides normalized to their non-phosphorylated counterparts ± SEM, n = 3. Statistics for RET phospho-Y687, -Y826, -Y900, -Y905, and -Y900/Y905 (JM-KD versus KD): ^∗∗∗∗^p \< 0.0001, ^∗∗∗^p = 0.009, two-way ANOVA Bonferroni test (black asterisks); ^∗^p \< 0.05, ^∗∗^p \< 0.005, multiple t test Sidak Bonferroni method (gray asterisks).\
(E) Enzymatic assay performed with RET JM-KD and RET KD (1 μM) incubated with increasing concentrations of ATP at a fixed (4 mg/ml) ABL peptide concentration. Data represent the mean ± SEM, n = 4 from two different protein preparations; ^∗∗∗∗^p \< 0.0001, two-way ANOVA Bonferroni test (left panel). Catalytic efficiency constants (k~cat~/K~M~, fold difference) are depicted in the right panel.](gr1){#fig1}

![Mapping Key JM-Segment Elements Required for RET Catalytic Activation\
(A) Enzymatic assay performed with purified recombinant (1 μM) RET JM-KD (with differing lengths) and RET KD varying the concentration of ABL peptide (sequence EAIYAAPFAKKK). Data are mean ± SEM and represent n = 3.\
(B) Catalytic efficiency constants (k~cat~/K~M~, fold difference) from (A).\
(C) WB analyses of purified recombinant RET JM-KD (2.5 μM, JM residues 661--705, RET JM661-KD), RET JM678-KD, RET JM698-KD, and RET KD treated with ATP (5 mM) and MgCl~2~ (10 mM) for 0--120 min using the indicated antibodies.\
(D) WB analyses of purified recombinant GST-RET fusions treated with ATP (5 mM) and MgCl~2~ (10 mM) for 0--80 min using the indicated antibodies. Total amount of protein was assessed by Coomassie blue staining.](gr2){#fig2}

![JM-Y687 Promotes RET Catalytic Activity and Rescues a Catalytically Deficient RET Activation-Loop Mutant Lacking Tyrosine\
(A) WB analysis of purified recombinant RET JM661-KD, JM678-KD, and JM-698-KD (2.5 μM) WT and Y687F mutants stimulated with ATP (5 mM) and MgCl~2~ (10 mM) for 0--80 min using the indicated antibodies.\
(B) WB analysis of purified recombinant RET JM661-KD (2.5 μM) WT and indicated Y/F mutants (Y900F, Y905F, Y900/905F, Y981F) with ATP (5 mM) and MgCl~2~ (10 mM) for 0--80 min using the indicated antibodies.\
(C) WB analysis of purified recombinant RET JM661-KD and RET KD (2.5 μM) WT, Y900/905F (YY/FF), and Y687/900/905F (YYY/FFF) mutants as indicated stimulated with ATP (5 mM) and MgCl~2~ (10 mM) for 0--90 min using the indicated antibodies. Total amount of protein was assessed by Coomassie blue staining.](gr3){#fig3}

![Crystallographic Identification of an Unexpected Activation-Loop Phospho-S909 Reveals Intrinsic RET Dual-Specificity Activity\
(A) Cartoon representation of phosphorylated RET JM-KD structure bound to PP1 inhibitor. Selected residues (including phosphorylated side chains) and secondary structure elements are depicted with discrete colors: JM-segment residues D707 to K716 (magenta), αC helix (purple), hinge residues (yellow), and activation segment residues (green) are shown.\
(B) Close-up of the activation-loop conformation and side chains in (A) (green) superposed with RET KD (tint wheat, PDB: [2IVV](pdb:2IVV){#intref0080}).\
(C) The 2Fo-Fc electron density map of phosphorylated activation-loop from PDB: [5FM2](pdb:5FM2){#intref0085} is shown as blue mesh countered at 1σ. Cartoon representation of basic residues engaged by either phospho-S909/Y928 from the JM-KD structure (upper panel, PDB: [5FM2](pdb:5FM2){#intref0090}) or phospho-Y905 (from PDB: [2IVV](pdb:2IVV){#intref0095}).\
(D) WB analyses using a specific antibody against RET phospho-S909 epitope (pSQG) using recombinant RET ICD WT, K758M, and S909A (upper panel) and in vitro time-course autoP assay in the presence of ATP (5 mM) and MgCl~2~ (10 mM) for 0--90 min (lower panel). Total RET protein was evaluated by Coomassie blue staining. Quantitation of WB data of [Figure 4](#fig4){ref-type="fig"}D is depicted. Data represent the mean of autoP (percentage) normalized to total protein ± SEM of the indicated antibodies, n = 3. Statistics: ^∗∗∗∗^p \< 0.0001, two-way ANOVA Bonferroni test versus control (WT).\
(E) WB analysis of in vitro time-course autoP assay using RET JM661-KD and RET KD core wild-type (WT) and R770A mutants after adding ATP (5 mM) and MgCl~2~ (10 mM) for 0--80 min using the indicated antibodies.](gr4){#fig4}

![Structure-Function Analysis of RET αC Hydrophobic Patch\
(A) Upper panel shows a cartoon representation of RET JM-KD structure, colored according to [Figure 4](#fig4){ref-type="fig"}A, with the superposition of PKA C-terminal residues (PDB: [1ATP](pdb:1ATP){#intref0100}). Lower panel shows two views of a surface representation of PKA catalytic subunit together with one of the RET JM-KD structures. The PKA C-terminal segment (pale brown), αC helix (purple), and activation loop (green) are depicted together with selected residues.\
(B) Close-up of a superposition of RET αC hydrophobic patch contact residues from the proximal JM-residues (D707 to W717) together with the C-terminal hydrophobic motif (FTDF) from PKA. Selected residues and secondary structural elements are depicted as in (A); some residues have been omitted for clarity. Alignment of RET sequences from different species indicating secondary structural elements and key residues (^∗^) implicated in the αC hydrophobic patch (lower panel).\
(C) WB analysis of in vitro time-course phosphorylation assay using RET JM661-KD WT and indicated mutants after addition of ATP (5 mM) and MgCl~2~ (10 mM) for 0--80 min using the indicated antibodies.\
(D) Enzymatic assay performed with recombinant purified (1 μM) RET JM661-KD WT and indicated mutants with increasing concentrations of ATP using the ABL peptide at a fixed concentration (4 mg/ml). The corresponding fold-difference in k~cat~/K~M~ values is shown in the lower panel. Data represent mean ± SEM, n = 2.](gr5){#fig5}

![RET W717 Contributes to the Assembly of the JM Hinge and R-Spine\
(A) WB analysis of in vitro time-course autoP assay using RET JM661-KD WT and indicated mutants (1 μM) after addition of ATP (5 mM) and MgCl~2~ (10 mM) for 0--90 min using the indicated antibodies. Quantitation of RET phospho-Y687 and -Y905 signal is shown; data represent mean ± SEM, n = 3, ^∗∗∗∗^p \< 0.0001, ^∗∗^p = 0.0014, two-way ANOVA Bonferroni test.\
(B) Cartoon representation of RET JM-KD crystal structure secondary structural elements, colored according to [Figure 4](#fig4){ref-type="fig"}A. Close-up of JM-hinge-composing residues (D714, K780, and W717) and R-spine-assembling residues (L779, L790, F893, H872, and D993) is shown; further selected residues and secondary structural elements are depicted as in [Figure 4](#fig4){ref-type="fig"}A. Some residues and structural elements have been omitted for clarity.\
(C) View of the C- and R-spines of RET JM-KD crystal structure as per text (see [Results](#sec2){ref-type="sec"} and [Discussion](#sec3){ref-type="sec"} for R-spine); in addition, the catalytic triad K758 (β-3 strand)-E775 (αC helix)-D892 (DFG motif) in sticks representation and the nucleotide moiety represented by the PP1 inhibitor (soft blue surface) are shown. The larger C-spine of RET contains residues emanating from the hydrophobic αF helix, through to nucleotide and capping N-lobe residues (i.e., L940, I944, L812, I880, L881, V882, V738, and A756).](gr6){#fig6}

![An Activation-Loop Serine Phospho-Site Is Required for RET Signaling In Vivo\
(A) Ectopic expression of *dRet*^*2B*^ (*dRet M955T*) and *dRet*^*2B*^*S946A* in the retina from the *GMR-Gal4 815* promoter.\
(B) Expression of *dRet*^*2B*^ from the *Gal4 765* promoter led to ectopic vein formation. *S946A* mutation rescued the wing defects. Scale bar, 500 μM.\
(C) Quantification of data shown in [Figure 6](#fig6){ref-type="fig"}B. The percentage of wings with ectopic veins was determined from three distinct transformants for each genotype. The number of individual flies counted from each transformant was 19, 30, and 23 for *dRet*^*2B*^ and 35, 17, and 23 for *dRet*^*2B*^*S946A*. ^∗∗^p \< 0.01, one-way ANOVA Bonferroni test.\
(D) WB analyses of S2 insect cells ectopically expressing *dRet* WT, M955T, and M955T/S946A, together with an *Actin*-promoter-driven *Gal4* construct using the indicated antibodies.](gr7){#fig7}

###### 

Data Collection and Refinement Statistics

                                                      RET JM-KDd3                 RETJM-KDd1
  --------------------------------------------------- --------------------------- ---------------------------
  Space group                                         P 6~3~ 2 2                  P 6~3~ 2 2
  Cell dimensions                                                                 
  a, b, c, Å                                          98.5, 98.5, 146.3           98.4, 98.4, 144.5
  α, β, γ                                             90.0°, 90.0°, 120.0°        90.0°, 90.0°, 120.0°
  Resolution (outer resolution shell), Å              40 -- 2.95 (3.11 -- 2.95)   50 -- 3.30 (3.48 -- 3.30)
  R~sym~ (%)                                          10.9 (79.5)                 0.17 (0.89)
  R~p.i.m.~ (%)                                       4.1 (30.1)                  0.05 (0.28)
  I/σ                                                 12.9 (2.8)                  10.9 (2.8)
  Completeness (%)                                    99.9 (100.0)                100 (100)
  Redundancy                                          7.9 (8)                     10.9 (11.3)
  Resolution (outer resolution shell), Å              40 -- 2.95 (3.37 -- 2.95)   55.0 -- 3.3 (3.75 -- 3.3)
  No. of unique reflections                           9,360                       6,686
  R~work~                                             19.9 (25.0)                 23.4 (25.7)
  R~free~[a](#tblfn1){ref-type="table-fn"}            22.4 (28.9)                 25.3 (29.4)
  No. of atoms                                        2,151                       2,105
  Wilson B factor                                     76.8                        79.4
  Average isotropic *B* factors, Å^2^                 74.4                        75.9
  Rmsds                                                                           
  Bonds, Å                                            0.002                       0.002
  Angles, °                                           0.66                        0.65
  Ramachandran plot (favored/allowed/disallowed), %   94.9/4.7/0.4                96.3/3.7/0.0

A total of 5% of the data were set aside to compute R~free~.
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